Table 1 Data from the study population

Age (years)

41.3 ± 13.5

45 ± 13

Female sex (N/%)

10/50

11/55

HAE disease duration (years)

27.4 ± 14

N.A.

Number of attacks^a

8 ± 7.6

N.A.

Attack-free period (days)^b

59 ± 71

N.A.

Danazol prohylaxis (N/%)

4/20

N.A.

C4 (mg/dl)

9.5 ± 4.5

N.A.

C1q (mg/l)

146 ± 20.3

N.A.

C1INH (mg/dl)

7 ± 3.4

N.A.

C1INH (%)

27.6 ± 12.2

N.A.

MABP (mmHg)

89 ± 10.4

88 ± 8

BCVA (LogMAR)

0.01 ± 0.1 (R); 0.01 ± 0.1 (L)

0.013 ± 0.03

IOP (mmHg)

16.5 ± 3 (R); 16.7 ± 2.9 (L)

16 ± 3

MD (median, dB)

−1.9 ***(R); − 2 ***(L)

0.3

PSD (median, dB)

2.16 **(R); 1.9 *(L)

1.6

VFI (range %)

92–98

98–100